Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2010

View Archived Issues

U.S. DoD funds Tekmira's development of RNAi agent against Ebola virus infection

New HIF-1-alpha activators claimed by sanofi-aventis

Ziopharm begins phase III palifosfamide trial in metastatic soft tissue sarcoma

Scientists identify NAbs with potent HIV-1 neutralization activity

Hexyl/methyl aminolevulinate photodynamic therapy does not damage cervical tissue

SRT-2104 improves metabolic function and glucose homeostasis in mice with DIO

BI-10773 is safe and tolerated in healthy subjects and in type 2 diabetes

ARC-4558 topical gel reduces pain in phase IIb trial in diabetes-associated neuropathy

KAI-4169 shows promise to treat secondary hyperparathyroidism in phase I trial

Aoxing confirms enrollment progress for phase III trial of TJSL capsules

Archer Biosciences begins dosing in third cohort of TPI-287 trial in metastatic melanoma

CytRx advances its bafetinib program in oncology

Seattle Genetics and Agensys begin phase I ASG-5ME trial in pancreatic cancer

German scientists disclose new HIF-mediated transcription inhibitors

Boehringer Ingelheim discovers new CB2 receptor agonists

Aegera reports survival data from phase I AEG-35156 combination trial

Inotek describes novel PARP inhibitors

Health Canada approves Winston Laboratories' Civanex for osteoarthritis pain

CVI Pharmaceuticals identifies novel lipid-lowering agents

Acorda Therapeutics receives NIH grant to develop GGF2 in heart failure

AiCuris presents novel anti-HIV agents

FDA accepts Mannkind's resubmission of Afrezza NDA

U.S. DoD funds AVI BioPharma's anti-Ebola and -Marburg virus research

Sepracor to change name to Sunovion Pharmaceuticals

FDA advisory committee votes for removal of first-line indication from Avastin label

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...